News

Keep up with the latest news from the NCI Center for Biomedical Informatics and Information Technology (CBIIT) and the data science communities.

With help from NCI’s Small Business Innovation Research (SBIR) program, researchers are refining a biophysical simulation technology using computational models for personalized cancer care.

A new $14 million project, funded by NIH’s Bridge2AI program, is turning the traditional biomarker concept on its ear. Instead of examining genetic or similar molecular characteristics, researchers are collecting data to look for voice biomarkers that can be linked to cancer.

Collaboration, cooperation, and the need for multimodal, multiscale data were central themes in a recent article on NCI’s efforts to develop a cancer research digital twin.

Learn more about a funding opportunity to develop AI-based models for predicting abdominal cancers. Applications may be accepted until May 8, 2023.

NCI-funded researchers recently began a partnership with AI experts from ConcertAI, LLC, to improve diversity in cancer clinical trials in the U.S. Gulf South region.

The NIH Common Fund’s Bridge to Artificial Intelligence program launched this month, aiming to bridge the gap between biomedical and behavioral research and artificial intelligence.

NCI’s Small Business Innovation Research Development Center released four new contract funding topics. The topics aim to advance work in the fields of wearable technologies, digital tools, and artificial intelligence.

Learn how NCI CT (Computed Tomography) imaging data sets enable the use of artificial intelligence in planning treatment for non-small cell lung cancer.

An NCI training grant and resources such as the NCI Cancer Research Data Commons’ Genomic Data Commons, in part, made it possible for this study to use multimodal deep learning. This model allowed researchers to examine pathology whole slide images and molecular profile data from 14 cancer types to enable more accurate patient outcome predictions.

An artificial intelligence (AI)-driven, computer-aided diagnosis (CAD) software first developed by code writers’ physicians at NIH has received FDA clearance for the detection and diagnosis of prostate cancer. The tool, called ProstatID, combines AI with traditional MRI scanning.